Drugs / CAR-20/19-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03019055 | Oct 2017 → Oct 2019 | chronic lymphocytic leukemia/small lymphocytic lymphoma | Medical College of Wisconsin | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CAR-20/19-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03019055 ↗ |
| Known as | LV20.19 | “Adult patients with B cell non-Hodgkin lymphoma or chronic lymphocytic leukemia were treated on a phase 1 dose escalation and expansion trial (NCT03019055) to evaluate the...” PMID 33020647 ↗ Oct 2020 |
| Action | Deplete | “a therapy that gets immune cells to fight cancer by changing them in the lab to find and destroy cancer cells” PMID 35603278 ↗ May 2022 |
| Modality | Cell therapy | “bispecific anti-CD20, anti-CD19 (LV20.19) CAR T cells” PMID 33020647 ↗ Oct 2020 |
| Route | Intravenous | “by IV injection” NCT03019055 ↗ |